Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?

Immunotherapy. 2023 Jan;15(1):5-8. doi: 10.2217/imt-2022-0157. Epub 2023 Jan 11.

Authors

Tarek Assi¹, Axel Le Cesne¹

Affiliation

¹ Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France.

PMID: 36628569
DOI: 10.2217/imt-2022-0157

No abstract available

Keywords: cancer immunology; checkpoint inhibitors; immunotherapy; sarcoma; soft tissue; trabectedin.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Alkylating / therapeutic use
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Sarcoma* / drug therapy
Trabectedin / therapeutic use

Substances

Trabectedin
Immune Checkpoint Inhibitors
Antineoplastic Agents, Alkylating